Literature DB >> 21949176

Editor's Note--to make the case--evidence is required: comment on "Making the case for selective use of statins in the primary prevention setting".

Rita F Redberg, Mitchell Katz, Deborah Grady.   

Abstract

Mesh：

Year:  2011        PMID： 21949176     DOI： 10.1001/archinternmed.2011.409

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN： 0003-9926


× No keyword cloud information.
  5 in total

Review 1.  The evolution or revolution of statin therapy in primary prevention: where do we go from here?

Authors:  Patricia Rehfield; Colin Kopes-Kerr; Michael Clearfield
Journal:  Curr Atheroscler Rep       Date:  2013-02       Impact factor: 5.113

2.  Statin use among older Finns stratified according to cardiovascular risk.

Authors:  Eveliina Upmeier; Maarit Jaana Korhonen; Arja Helin-Salmivaara; Risto Huupponen
Journal:  Eur J Clin Pharmacol       Date:  2012-06-17       Impact factor: 2.953

3.  Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial.

Authors:  Beatrice A Golomb; Marcella A Evans; Joel E Dimsdale; Halbert L White
Journal:  Arch Intern Med       Date:  2012-08-13

Review 4.  A point-by-point response to recent arguments against the use of statins in primary prevention: this statement is endorsed by the American Society for Preventive Cardiology.

Authors:  Parag H Joshi; Sameer Chaudhari; Michael J Blaha; Steven R Jones; Seth S Martin; Wendy S Post; Christopher P Cannon; Gregg C Fonarow; Nathan D Wong; Ezra Amsterdam; John W Hirshfeld; Roger S Blumenthal
Journal:  Clin Cardiol       Date:  2012-06-06       Impact factor: 2.882

5.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

Authors:  B Mihaylova; J Emberson; L Blackwell; A Keech; J Simes; E H Barnes; M Voysey; A Gray; R Collins; C Baigent
Journal:  Lancet       Date:  2012-05-17       Impact factor: 79.321
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.